NCT00866047 · OUTCOME
Chemistry Laboratory Abnormalities >/= Grade 3
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- up to 12 months
What was measured
Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.
Analysis population: All participants who received treatment
Groups in this outcome
Brentuximab Vedotin
Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Brentuximab Vedotin | 58 |
|---|
Reported measurements
Any >/= Grade 3 chemistry laboratory abnormality
Values in participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Brentuximab Vedotin | 13 | Not reported | Not reported | Not reported | Not reported |
|---|
Aspartate aminotransferase (high)
Values in participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Brentuximab Vedotin | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Calcium (low)
Values in participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Brentuximab Vedotin | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
Glucose (high)
Values in participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Brentuximab Vedotin | 4 | Not reported | Not reported | Not reported | Not reported |
|---|
Potassium (low)
Values in participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Brentuximab Vedotin | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Sodium (low)
Values in participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Brentuximab Vedotin | 1 | Not reported | Not reported | Not reported | Not reported |
|---|
Urate (high)
Values in participants · Interval/dispersion: Not reported| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Brentuximab Vedotin | 3 | Not reported | Not reported | Not reported | Not reported |
|---|
Complete source fields
- classes
- title
- Any >/= Grade 3 chemistry laboratory abnormality
- title
- Aspartate aminotransferase (high)
- title
- Calcium (low)
- title
- Glucose (high)
- title
- Potassium (low)
- title
- Sodium (low)
- title
- Urate (high)
- description
- Counts of study participants with post-baseline chemistry laboratory abnormalities of Grade 3 or greater per NCI CTCAE version 3.0. Participants with multiple occurrences of a laboratory abnormality within a category are counted once in that category.
- groups
- description
- Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
- id
- OG000
- title
- Brentuximab Vedotin
- param Type
- NUMBER
- population Description
- All participants who received treatment
- reporting Status
- POSTED
- time Frame
- up to 12 months
- title
- Chemistry Laboratory Abnormalities >/= Grade 3
- type
- SECONDARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice
Triangle